{"id":"NCT00611026","sponsor":"Pfizer","briefTitle":"Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.","officialTitle":"12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2008-02-08","resultsPosted":"2011-01-12","lastUpdate":"2011-02-02"},"enrollment":2417,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder"],"interventions":[{"type":"DRUG","name":"Tolterodine ER","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Fesoterodine","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"PLACEBO_COMPARATOR"},{"label":"3","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder","primaryOutcome":{"measure":"Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-1.62,"sd":0.07},{"arm":"Tolterodine ER","deltaMin":-1.74,"sd":0.06},{"arm":"Fesoterodine","deltaMin":-1.95,"sd":0.05}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"0.0228"},{"comp":"OG001 vs OG002","p":"0.0072"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":227,"countries":["United States","Brazil","Bulgaria","Canada","Colombia","Costa Rica","Estonia","Germany","Greece","Hungary","India","Ireland","Latvia","Lithuania","Malaysia","Poland","Romania","Russia","Singapore","Slovakia","South Africa","South Korea","Spain","Sweden","Ukraine"]},"refs":{"pmids":["37160401","35881009"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221046&StudyName=Clinical%20Trial%20to%20Evaluate%20the%20Efficacy%20and%20Safety%20of%20Fesoterodine%20in%20Comparison%20to%20Tolterodine%20ER%20in%20Patients%20with%20Overactive%20Bladder."]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":478},"commonTop":["Dry mouth","Constipation","Polyuria","Headache","Dyspepsia"]}}